Regulatory approval for ozanimod is expected in the second half of this year. Results from a couple of late-stage studies of Revlimid in additional indications are anticipated in 2018. Late-stage results from two studies of promising candidate luspatercept in treating myelodysplastic syndromes (MDS) and beta-thalassemia are also expected in mid-2018. In addition, Celgene intends to file for FDA approval of fedratinib in treating myelofibrosis in the middle of the year. The company is picking up fedratinib with its pending acquisition of Impact Biomedicines.
Source : http://www.nwitimes.com/business/investment/markets-and-stocks/will-be-celgene-corporation-s-best-year-yet/article_c760319e-7422-5876-a4ba-b99971b363bd.html